Work

A phase I (Ph1) study of dasatinib (D) with cetuximab (Cet) /radiation (IMRT) +/- cisplatin (P) in stage II, III/IV head and neck squamous cell carcinoma (HNSCC).

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.e17036

Authors: Shanthi Marur, Hao Wang, Harry Quon, Christine H. Chung, Maura L. Gillison, Nishant Agrawal, Jeremy Richmon, Rathan M. Subramaniam, Wayne Koch, Christine Gail Gourin, Arlene A. Forastiere

Institutions: Johns Hopkins University, Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, The Ohio State University

Language: English

Topic: Head and Neck Cancer Studies

Subfield: Otorhinolaryngology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2601666309

Cites:

Cited by: 2

Related to: 10